Search research articles
Contact Us
Filters
Showing results (11-20 of 387) with videos related to
Page
of 39
Sort By:
Cancer Biotherapy & Radiopharmaceuticals
|
May 5, 2005
Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma
Gregory A Wiseman, Thomas E Witzig
Current Treatment Options in Oncology
|
April 30, 2004
Waldenström macroglobulinemia
Irene M Ghobrial, Thomas E Witzig
Therapeutic Advances in Hematology
|
April 5, 2013
Initial therapy of mantle cell lymphoma
David J Inwards, Thomas E Witzig
Current Treatment Options in Oncology
|
June 12, 2002
Heavy chain disease
Thomas E Witzig, Dietlind L Wahner-Roedler
Plos One
|
July 18, 2013
A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling
Guangzhen Hu, Thomas E Witzig, Mamta Gupta
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2004
Thalidomid: current role in the treatment of non-plasma cell malignancies
Shaji Kumar, Thomas E Witzig, S Vincent Rajkumar
Oncotarget
|
February 6, 2016
Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective
Jose Caetano Villasboas, Stephen M Ansell, Thomas E Witzig
Proceedings (Baylor University. Medical Center)
|
April 2, 2013
Recurrent acute inflammatory demyelinating polyradiculoneuropathy following R-CHOP treatment for non-Hodgkin lymphoma
Jackson J Liang, Preet P Singh, Thomas E Witzig
CA: a Cancer Journal for Clinicians
|
May 14, 2005
Targeting apoptosis pathways in cancer therapy
Irene M Ghobrial, Thomas E Witzig, Alex A Adjei
Journal of Hematology & Oncology
|
November 25, 2010
Targeted therapy in lymphoma
Patrick B Johnston, RuiRong Yuan, Franco Cavalli, et al.
Page
of 39
Search research articles
Search
Showing results (11-20 of 387) with videos related to
Sort By:
Page
of 39
Cancer Biotherapy & Radiopharmaceuticals
|
May 5, 2005
Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma
Gregory A Wiseman, Thomas E Witzig
Current Treatment Options in Oncology
|
April 30, 2004
Waldenström macroglobulinemia
Irene M Ghobrial, Thomas E Witzig
Therapeutic Advances in Hematology
|
April 5, 2013
Initial therapy of mantle cell lymphoma
David J Inwards, Thomas E Witzig
Current Treatment Options in Oncology
|
June 12, 2002
Heavy chain disease
Thomas E Witzig, Dietlind L Wahner-Roedler
Plos One
|
July 18, 2013
A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling
Guangzhen Hu, Thomas E Witzig, Mamta Gupta
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2004
Thalidomid: current role in the treatment of non-plasma cell malignancies
Shaji Kumar, Thomas E Witzig, S Vincent Rajkumar
Oncotarget
|
February 6, 2016
Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective
Jose Caetano Villasboas, Stephen M Ansell, Thomas E Witzig
Proceedings (Baylor University. Medical Center)
|
April 2, 2013
Recurrent acute inflammatory demyelinating polyradiculoneuropathy following R-CHOP treatment for non-Hodgkin lymphoma
Jackson J Liang, Preet P Singh, Thomas E Witzig
CA: a Cancer Journal for Clinicians
|
May 14, 2005
Targeting apoptosis pathways in cancer therapy
Irene M Ghobrial, Thomas E Witzig, Alex A Adjei
Journal of Hematology & Oncology
|
November 25, 2010
Targeted therapy in lymphoma
Patrick B Johnston, RuiRong Yuan, Franco Cavalli, et al.
Page
of 39